PHACTR1 and coronary artery disorder: On the other hand, CRISPR/Cas9 genome editing have helped to establish an association between phosphatase and actin regulator 1 (PHACTR1) intronic SNPs and the locus of myocyte enhancer factor 2 (MEF2) binding site, suggesting the involvement of an unknown mechanisms that influence CAD/MI (coronary artery disease/myocardial infarction) risk in the vascular endothelium.